GlipiZIDE XL Side Effects
Generic name: glipizide
Medically reviewed by Drugs.com. Last updated on Jun 21, 2021.
Note: This document contains side effect information about glipizide. Some dosage forms listed on this page may not apply to the brand name GlipiZIDE XL.
Applies to glipizide: oral tablets.
Side effects include:
Conventional tablets: Nausea, anorexia, vomiting, pyrosis, gastralgia, diarrhea, constipation.
Extended-release tablets: Dizziness, diarrhea, nervousness, tremor, hypoglycemia, flatulence.
Glipizide (the active ingredient contained in GlipiZIDE XL) metformin hydrochloride fixed combination: Upper respiratory tract infection, diarrhea, dizziness, hypertension, nausea/vomiting, musculoskeletal pain, headache, abdominal pain, urinary tract infection.
For Healthcare Professionals
Applies to glipizide: compounding powder, oral tablet, oral tablet extended release.
General
The more commonly reported side effects have included dizziness, diarrhea, nervousness, tremor, hypoglycemia, and flatulence.[Ref]
Metabolic
Disulfiram-like reactions have been reported with sulfonylureas. Clinical experience has shown this drug to have a low incidence of disulfiram-like alcohol reactions.[Ref]
Common (1% to 10%): Hypoglycemia
Uncommon (less than 1%): Thirst
Frequency not reported: Disulfiram like reactions, hepatic porphyria, hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), elevation of LDH[Ref]
Hematologic
Frequency not reported: Leucopenia, agranulocytosis, thrombocytopenia, aplastic anemia, hemolytic anemia, pancytopenia[Ref]
Cardiovascular
Common (1% to 10%): Syncope
Uncommon (less than 1%): Arrhythmia, flushing, hypertension[Ref]
Hepatic
Frequency not reported: Impaired hepatic function, hepatitis, jaundice, mild to moderate ALT, LDH, alkaline phosphatase elevations
Postmarketing reports: Cholestatic and hepatocellular forms of liver injury accompanied by jaundice[Ref]
Dermatologic
Dermatologic side effects frequently disappear with continued therapy. Photosensitivity has been reported with other sulfonylureas.[Ref]
Common (1% to 10%): Sweating, pruritus
Uncommon (less than 1%): Rash, urticaria
Frequency not reported: Rash, erythema, morbilliform or maculopapular eruptions, urticaria, pruritus, eczema[Ref]
Gastrointestinal
Common (1% to 10%): Nausea, diarrhea, constipation, gastralgia, vomiting, flatulence, dyspepsia
Uncommon (less than 1%): Anorexia, trace blood in stool
Frequency not reported: Gastrointestinal irritation, gastrointestinal bleeding
Postmarketing reports: Abdominal pain[Ref]
Gastrointestinal side effects appear to be dose-related and may disappear on division or reduction of dosage.[Ref]
Genitourinary
Common (1% to 10%): Polyuria
Uncommon (less than 1%): Dysuria[Ref]
Musculoskeletal
Common (1% to 10%): Arthralgia, leg cramps, myalgia[Ref]
Nervous system
Common (1% to 10%): Headache, dizziness, nervousness, tremors, paresthesia, hypesthesia
Uncommon (less than 1%): Migraine
Frequency not reported: Drowsiness[Ref]
Ocular
Common (1% to 10%): Blurred vision
Uncommon (less than 1%): Pain in the eye, conjunctivitis, retinal hemorrhage
Frequency not reported: Diplopia, abnormal vision, visual impairment, decreased vision[Ref]
Other
Common (1% to 10%): Asthenia, pain
Uncommon (less than 1%): Chills, edema
Frequency not reported: Vertigo, malaise[Ref]
Psychiatric
Common (1% to 10%): Insomnia, anxiety, depression
Frequency not reported: Confusion[Ref]
Respiratory
Common (1% to 10%): Rhinitis
Uncommon (less than 1%): Pharyngitis, dyspnea[Ref]
Renal
Frequency not reported: Mild to moderate BUN and creatinine elevations
More about GlipiZIDE XL (glipizide)
- Check interactions
- Pricing & coupons
- Reviews (10)
- Drug images
- Dosage information
- During pregnancy
- Drug class: sulfonylureas
- Breastfeeding
Patient resources
Other brands
Professional resources
Related treatment guides
References
1. "Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals (2002):
2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
3. Cerner Multum, Inc. "Australian Product Information." O 0
4. Feinglos MN, Lebovitz HE "Long-term safety and efficacy of glipizide." Am J Med 75 (1983): 60-6
5. Moder KG, Schwenk NM "A coproporphyria-like syndrome induced by glipizide." Mayo Clin Proc 66 (1991): 312-6
6. Asplund K, Wiholm BE, Lundman B "Severe hypoglycaemia during treatment with glipizide." Diabet Med 8 (1991): 726-31
7. Brogden RN, Heel RC, Pakes GE, Speight TM, Avery GS "Glipizide: a review of its pharmacological properties and therapeutic use." Drugs 18 (1979): 329-53
8. Lebovitz HE "Glipizide: a second-generation sulfonylurea hypoglycemic agent. Pharmacology, pharmacokinetics and clinical use." Pharmacotherapy 5 (1985): 63-77
9. Prendergast BD "Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents." Clin Pharm 3 (1984): 473-85
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.